These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20559603)

  • 1. [Differences in the use of tigecycline between ICU patients and non-ICU patients].
    Alvarez-Lerma F; Blanco L; Rodríguez JA; Grau S; Conde-Estévez D; Luque S
    Rev Esp Quimioter; 2010 Jun; 23(2):63-71. PubMed ID: 20559603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting.
    Montravers P; Dupont H; Bedos JP; Bret P;
    Intensive Care Med; 2014 Jul; 40(7):988-97. PubMed ID: 24871500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: observational study focus on tigecycline.
    Zimmermann JB; Horscht JJ; Weigand MA; Bruckner T; Martin EO; Hoppe-Tichy T; Swoboda S
    Int J Antimicrob Agents; 2013 Nov; 42(5):436-42. PubMed ID: 24055255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights.
    Ibrahim MM; Abuelmatty AM; Mohamed GH; Nasr MA; Hussein AK; Ebaed MED; Sarhan HA
    Drug Des Devel Ther; 2018; 12():4171-4179. PubMed ID: 30584281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients.
    Maseda E; Suárez-de-la-Rica A; Anillo V; Salgado P; Tamayo E; García-Bernedo CA; Ramasco F; Villagrán MJ; López-Tofiño A; Giménez MJ; Granizo JJ; Hernández-Gancedo C; Aguilar L; Gilsanz F
    Rev Esp Quimioter; 2015 Feb; 28(1):47-53. PubMed ID: 25690145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tigecycline for treatment of severe infections in intensive care: a drug use evaluation].
    Jung B; Chanques G; Ghiba M; Cisse M; Rossel N; Perrigault PF; Souche B; Jean-Pierre H; Jaber S
    Ann Fr Anesth Reanim; 2010 May; 29(5):354-60. PubMed ID: 20347565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.
    Maseda E; Denis SE; Riquelme A; Gilsanz F
    Rev Esp Quimioter; 2013 Mar; 26(1):56-63. PubMed ID: 23546465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline in the treatment of ventilator-associated pneumonia: experience from the Latin American Tigecycline Use Registry.
    Curcio D; Castagnino J; Vazquez W; Vergara G; Curiale A;
    Infez Med; 2010 Mar; 18(1):27-34. PubMed ID: 20424523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections.
    Liebenstein T; Schulz LT; Viesselmann C; Bingen E; Musuuza J; Safdar N; Rose WE
    Pharmacotherapy; 2017 Feb; 37(2):151-158. PubMed ID: 27983753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing frequency of Pseudomonas aeruginosa infections during tigecycline use.
    Ulu-Kilic A; Alp E; Altun D; Cevahir F; Kalın G; Demiraslan H
    J Infect Dev Ctries; 2015 Mar; 9(3):309-12. PubMed ID: 25771470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.
    Chemaly RF; Hanmod SS; Jiang Y; Rathod DB; Mulanovich V; Adachi JA; Rolston KV; Raad II; Hachem RY
    Medicine (Baltimore); 2009 Jul; 88(4):211-220. PubMed ID: 19593226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tigecycline treatment of critically ill patients: the LatinUser experience.
    Curcio D; Vargas SW; Ugarte Ubiergo S; Varón F; Rojas Suarez J; Paz Chávez C; Curiale A;
    Curr Clin Pharmacol; 2011 Feb; 6(1):18-25. PubMed ID: 21235466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome.
    Nseir S; Di Pompeo C; Cavestri B; Jozefowicz E; Nyunga M; Soubrier S; Roussel-Delvallez M; Saulnier F; Mathieu D; Durocher A
    Crit Care Med; 2006 Dec; 34(12):2959-66. PubMed ID: 17012911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
    Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
    Eckmann C; Montravers P; Bassetti M; Bodmann KF; Heizmann WR; Sánchez García M; Guirao X; Capparella MR; Simoneau D; Dupont H
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients.
    Kuo SC; Wang FD; Fung CP; Chen LY; Chen SJ; Chiang MC; Hsu SF; Liu CY
    J Microbiol Immunol Infect; 2011 Feb; 44(1):45-51. PubMed ID: 21531352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
    Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
    Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.